A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.

Trial Details

NCT ID
NCT05201781
Phase
PHASE4
Sponsor
Janssen Research & Development, LLC
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • Cilta-cel
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Duarte, California, United States|34.13945,-117.97729
  • San Francisco, California, United States|37.77493,-122.41942
  • Stanford, California, United States|37.42411,-122.16608
  • Tampa, Florida, United States|27.94752,-82.45843

Key Eligibility Criteria

  • Participants who have received at least one dose of cilta-cel in a Company-sponsored clinical study
  • Participants who have provided informed consent for this study

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →